Pay in 4 interest-free payments of $6.14 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
A mutant strain lacking CgAtg1, an autophagy-inducing factor, was generated and confirmed to be deficient for autophagy
Additional safety considerations include: Acute pancreatitis risk : Patients should be monitored for severe abdominal pain Gallbladder disease : Including cholelithiasis and cholecystitis Dehydration and acute kidney injury : Particularly with gastrointestinal side effects Hypoglycemia : When used with insulin or sulfonylureas in patients with diabetes Diabetic retinopathy complications : Particularly with semaglutide in patients with pre-existing retinopathy Patients with hypothyroidism should undergo thyroid function monitoring when starting weight loss injections
Marine compounds have recently gained the attention of the pharmaceutical and food sectors as a source of potential antioxidants (Ngo et al., 2011)
US$ 22.70
US$ 24.67
US$ 28.07
US$ 23.55
US$ 23.68
